Abstracts tagged "Myopathies"

Abstract Number: 0295 • ACR Convergence 2023
Pneumocystis Jirovecii Pneumonia in Patients with Inflammatory Myopathies
Cody Bruggemeyer¹, Sanket Shah², Didem Saygin³ and Mike Putman⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis Jirovecii Pneumonia (PJP) is an opportunistic fungal infection with high morbidity and mortality rates. Few studies to date have assessed the incidence of…
Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Verónica Pulito-Cueto¹, David Iturbe-Fernández², Victor Mora-Cuesta², Joao Carlos Batista-Liz¹, Belén Atienza-Mateo³, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Miguel A Gonzalez-Gay⁴, Jose Cifrian⁵, Ricardo Blanco¹ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…
Abstract Number: 2575 • ACR Convergence 2023
Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening
Alexander Oldroyd¹, Francisca Bozan¹, Xia Lyu², Patrick Gordon³, David Isenberg⁴, Neil McHugh⁵, Harsha Gunawardena⁶, Patrick Kiely⁷, Janine Lamb¹, Pedro Machado⁸, James Miller⁹, Sarah Tansley⁵ and Hector Chinoy¹⁰, ¹University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Shanghai Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, ³NHS, London, United Kingdom, ⁴University College London, London, United Kingdom, ⁵University of Bath, Bath, United Kingdom, ⁶North Bristol NHS Trust, Bristol, United Kingdom, ⁷St George’s University Hospitals NHS Foundation Trust, London, United Kingdom, ⁸Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁹Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ¹⁰The University of Manchester, Sale, United Kingdom
Background/Purpose: Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within three years prior to or following IIM onset. The International Guideline…
Abstract Number: 0296 • ACR Convergence 2023
Does Presence of Anti-SSa and Ro52 Influence the Progression of Interstitial Lung Disease (ILD) in Idiopathic Inflammatory Myopathies (IIM)
Sonali Narain¹, Can Hu², Michael Liu¹, Kourosh Shargani³ and Galina Marder¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Fort Lee, NJ, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
Background/Purpose: Anti-SSa and Ro52 are commonly present in IIM. We previously reported an association of a more severe early course of IIM-ILD with positive Ro52.…
Abstract Number: 1914 • ACR Convergence 2023
Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes
Cristina Corrales Selaya¹, David Martínez-Lopez², Diana Prieto-Peña¹, Fabricio Benavides¹, Jose Luis Martin-Varillas³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterised mainly by the presence of inflammation and muscle weakness. The main subtypes of…
Abstract Number: 2577 • ACR Convergence 2023
Frequency of Atherosclerotic Cardiovascular Disease Following a Diagnosis of Idiopathic Inflammatory Myopathy: Data from a Large National Registry
Astia Allenzara¹, Carolina Alvarez², Amanda Nelson³ and Galen Foulke⁴, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: Idiopathic inflammatory myopathies confer an increased risk of morbidity from cardiovascular disease. Prior work has noted more than double risk of cardiovascular events for…
Abstract Number: 0297 • ACR Convergence 2023
Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series
Eaman Alhassan¹, Belina Yi², Jack Rodman¹ and Leanna Wise³, ¹University of Southern California, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA, ³LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: There is little to no data about the presentation and clinical course of anti-melanoma differentiation-associated gene-5 antibody (anti-MDA-5) dermatomyositis patients in a primarily U.S.…
Abstract Number: 1946 • ACR Convergence 2023
Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis
Rohit Aggarwal¹, Namita Goyal², Diana Lam³, Allen Ng³, Richard Leff⁴, Kathryn Ray³, Eunmi Park³ and Noreen Henig³, ¹University of Pittsburgh, Pittsburgh, PA, ²UCI Health, Orange, CA, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Chadds Ford, PA
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases characterized by muscle inflammation and weakness. In a collagen-induced myositis mouse model, immunoproteasome inhibition has…
Abstract Number: 2578 • ACR Convergence 2023
Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles
Jenny Wei¹, Mark Tarnopolsky², Marie Hudson³, Ross Mitchell⁴, Katherine Buhler⁵, Antoine Dufour⁶, Luiz de Almeida⁶, Paul R. Fortin⁷, Eric Boilard⁸, Yann Becker⁸, Erin Hatcher², Mei Feng Zhang⁶, Marvin Fritzler⁶ and May Choi⁶, ¹University of Toronto, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Calgary; Cumming School of Medicine, Calgary, AB, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁸Université Laval, Quebec City, QC, Canada
Background/Purpose: Sporadic inclusion body myositis (sIBM) is a subset of autoimmune inflammatory myopathies (AIM) that is often challenging to diagnose. The objective of this study…
Abstract Number: 0298 • ACR Convergence 2023
Accuracy of the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criteria and Myositis-Specific Autoantibodies-Based Classification Criteria for Classifying Patients with Idiopathic Inflammatory Myopathy
Tatiana Cobo¹, Marta Domínguez², Anna Pros³, Jose Luís Tandaipán⁴, Laura Nuño⁵, JULIA MARTINEZ BARRIO⁶, Vega Jovani⁷, Fredeswinda Romero⁸, Maria Esther Ruiz Lucea⁹, Eva Tomero Muriel¹⁰, Ernesto Trallero Araguás¹¹, Javier Narvaez¹², Jordi Camins Fàbregas¹³, ALBERTO MARIANO RUIZ ROMAN¹⁴, Jesus Loarce-Martos¹⁵, Annika Nack¹⁶, Esmeralda Delgado-Frías¹⁷, Francisca Sivera¹⁸, carolina Merino¹⁹, Antonio Juan Mas²⁰, Alejandro Gómez Gómez¹, Jose-Maria Pego-Reigosa²¹, Maria Martin-Lopez²², Jesús Alejandro Valero²³, Carmen carrasco-Cubero²⁴, Mercedes Freire González²⁵, Iñigo Rúa-Figueroa²⁶, Nuria Lozano Rivas²⁷, Julio David Suarez Cuba²⁸, Ana Isabel Turrión Nieves²⁹, María Ángeles Puche Larrubia³⁰ and Patricia Alcocer Amores³¹, ¹Department of Rheumatology, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Department of Rheumatology, Hospital del Mar, Barcelona, Spain, ⁴Department of Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ⁶Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁷Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ⁸IIS-HU Fundación Jiménez Díaz, Madrid, Spain, ⁹Basurto University Hospital, Bilbao, Spain, ¹⁰Rheumatology, Hospital La Princesa, Madrid, Spain, ¹¹Department of Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain, ¹²Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Department of Rheumatology, Hospital General de Granollers, Barcelona, Spain, ¹⁴Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁵Ramón y Cajal University Hospital, Madrid, Spain, ¹⁶Department of Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹⁷Department of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ¹⁸Department of Rheumatology, Hospital General Universitario de Elda, Alicante, Spain, ¹⁹Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ²⁰Hospital Universitario Son Llàtzer, Mallorca, Spain, ²¹Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ²²Hospital 12 de Octubre, Madrid, Spain, ²³Department of Rheumatology, Hospital Universitario Donostia, San Sebastián, Spain, ²⁴Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ²⁵Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²⁶Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²⁷Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁸Department of Rheumatology, Hospital Universitario Príncipe de Asturias, Madrid, Spain, ²⁹Department of Rheumatology, Hospital Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ³⁰Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ³¹Department of Rheumatology, Hospital Universitario HM Sanchinarro, Madrid, Spain
Background/Purpose: Limitations of the 2017 EULAR/ACR classification criteria have been suggested for classifying patients with idiopathic inflammatory myopathies (IIMs) and myositis-specific antibodies (MSAs). On this…
Abstract Number: 1948 • ACR Convergence 2023
The Influence of Specific Myositis Antibodies on the Development of Interstitial Lung Disease
Ting-Yuan Lan¹, Tai-Ju Lee¹, Kuan-Yen Lin², Jui-Hung Kao³, Chiao-Feng Cheng⁴, Cheng-Hsun Lu⁴, Chieh-Yu Shen⁴, Ko-Jen Li⁴ and Song-Chou Hsieh⁴, ¹National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ²National Taiwan University Hsinchu branch, Hsinchu, Taiwan, ³National Taiwan University Hospital Yunlin branch, Yunlin, Taiwan, ⁴National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Interstitial Lung Disease (ILD), prevalent in Idiopathic Inflammatory Myositis (IIM) patients, significantly impacts prognosis. Certain myositis-specific antibodies, including anti-MDA5 and anti-aminoacyl-tRNA synthetases (ARS), are…
Abstract Number: 2580 • ACR Convergence 2023
High-intensity Resistance Training Improves Quality of Life, Muscle Endurance and Strength in Patients with Myositis
Kasper Jensen¹, Per Aagaard², Charlotte Suetta³, Jakob Nielsen², Rune Bech⁴, Henrik Schrøder¹, Casper Simonsen¹, Jan Christensen¹ and Louise Pyndt Diederichsen⁵, ¹University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark, ²University of Southern Denmark, Odense, Denmark, ³Bispebjerg Hospital, Copenhagen, Denmark, ⁴Zealand University Hospital, Koege, Dragør, Denmark, ⁵University Hospital of Copenhagen, Rigshospitalet, Dragør, Denmark
Background/Purpose: Myositis is associated with muscle impairment, which impacts quality of life. The purpose of this study was to investigate the effects of high-intensity strength…
Abstract Number: 100 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools
Darcisio Antonio¹, Taciana Fernandes¹, Adriana Elias², Teresa Robazzi³, Ana Julia Moraes⁴, Sheila Oliveira⁵, Flavio Sztajnbok⁶, Luciana Carvalho⁷, Luciana Marques⁸, Silvana Sacchetti⁹, Maria Teresa Terreri¹⁰, Simone Appenzelle¹¹, Roberto Marini¹², Carlos Rabello Jr¹³, Cristina Magalhaes¹⁴, Melissa Fraga¹⁵, Marcia Bandeira¹⁶, Iloite Scheibel¹⁷, Isabela Daud², Beatriz Carneiro², Claudio Len¹⁸, Clovis Silva¹⁹ and Claudia Magalhaes²⁰, ¹Universidade Estadual Paulista (UNESP) Botucatu, Brazil, ²Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, ³Universidade Federal da Bahia, Brazil, ⁴Universidade Federal do Para, Brazil, ⁵Universidade Federal do Rio de janeiro, Rio de Janeiro, ⁶Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁷Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, ⁸Hospital Albert Sabin, Brazil, ⁹Santa Casa de Sao Paulo, Brazil, ¹⁰UNIFESP, São Paulo, Brazil, ¹¹University of Campinas, Campinas, Sao Paulo, Brazil, ¹²UNICAMP, São Paulo, Brazil, ¹³Hospital Geral de Fortaleza, Brazil, ¹⁴Hospital Jose de Alencar - Brasilia, Brazil, ¹⁵Hospital Darcy Vargas, Brazil, ¹⁶Hospital Pequeno Principe- Curitiba, Brazil, ¹⁷Hospital Conceição de Porto Alegre, Brazil, ¹⁸Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, ¹⁹Universidade de São Paulo, São Paulo, Brazil, ²⁰São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil
Background/Purpose: Muscle weakness is often progressive and persistent in Juvenile Dermatomyositis (JDM). Muscle strength testing is useful for evaluating severity of muscle weakness. There is…
Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Beatriz Carneiro¹, Adriana Elias¹, Teresa Robazzi², Ana Julia Moraes³, Sheila Oliveira⁴, Flavio Sztajnbok⁵, Luciana Carvalho⁶, Luciana Marques⁷, Silvana Sacchetti⁸, Maria Teresa Terreri⁹, Simone Appenzelle¹⁰, Roberto Marini¹¹, Andre Cavalcante¹², Marcia Bandeira¹³, Cristina Magalhaes¹⁴, Melissa Fraga¹⁵, Iloite Scheibel¹⁶, Isabela Daud¹, Darcisio Antonio¹⁷, Claudio Len¹⁸, Clovis Silva¹⁹, Taciana Fernandes¹⁷ and Claudia Magalhaes²⁰, ¹Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, ²Universidade Federal da Bahia, Brazil, ³Universidade Federal do Para, Brazil, ⁴Universidade Federal do Rio de janeiro, Rio de Janeiro, ⁵Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, ⁷Hospital Albert Sabin, Brazil, ⁸Santa Casa de Sao Paulo, Brazil, ⁹UNIFESP, São Paulo, Brazil, ¹⁰University of Campinas, Campinas, Sao Paulo, Brazil, ¹¹UNICAMP, São Paulo, Brazil, ¹²Hospital Materno-Infantil de Goiania, Brazil, ¹³Hospital Pequeno Principe- Curitiba, Brazil, ¹⁴Hospital Jose de Alencar - Brasilia, Brazil, ¹⁵Hospital Darcy Vargas, Brazil, ¹⁶Hospital Conceição de Porto Alegre, Brazil, ¹⁷Universidade Estadual Paulista (UNESP) Botucatu, Brazil, ¹⁸Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, ¹⁹Universidade de São Paulo, São Paulo, Brazil, ²⁰São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…
Abstract Number: 1871 • ACR Convergence 2022
Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
Zi Ying Li¹, Siyi Huang², Kevin Xi³, Deepan Dalal⁴ and Anthony Reginato⁵, ¹Roger Williams Medical Center, Providence, RI, ²UCSF Fresno, Fresno, CA, ³Brown University, Providence, ⁴Brown University School of Medicine, Providence, RI, ⁵Brown University, Providence, RI
Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].